755 related articles for article (PubMed ID: 31365094)
41. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016.
Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A;
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054
[TBL] [Abstract][Full Text] [Related]
42. A novel KPC-166 in ceftazidime/avibactam resistant ST307 Klebsiella pneumoniae causing an outbreak in intensive care COVID Unit, Italy.
Piazza A; Mattioni Marchetti V; Bielli A; Biffignandi GB; Piscopiello F; Giudici R; Tartaglione L; Merli M; Vismara C; Migliavacca R
J Microbiol Immunol Infect; 2024 Jun; 57(3):457-469. PubMed ID: 38584042
[TBL] [Abstract][Full Text] [Related]
43. KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.
Di Pilato V; Aiezza N; Viaggi V; Antonelli A; Principe L; Giani T; Luzzaro F; Rossolini GM
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106265
[TBL] [Abstract][Full Text] [Related]
44. Isolation of a Ceftazidime-Avibactam-Resistant
Shen S; Shi Q; Han R; Guo Y; Yang Y; Wu S; Yin D; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0184021. PubMed ID: 35080422
[No Abstract] [Full Text] [Related]
45. KPC-Mediated Resistance to Ceftazidime-Avibactam and Collateral Effects in Klebsiella pneumoniae.
Findlay J; Poirel L; Juhas M; Nordmann P
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0089021. PubMed ID: 34228551
[TBL] [Abstract][Full Text] [Related]
46. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
[TBL] [Abstract][Full Text] [Related]
47. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
[TBL] [Abstract][Full Text] [Related]
48. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
[TBL] [Abstract][Full Text] [Related]
50. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
[TBL] [Abstract][Full Text] [Related]
51. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
52. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
Munoz-Price LS; Reeme AE; Buchan BW; Mettus RT; Mustapha MM; Van Tyne D; Shields RK; Doi Y
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332070
[TBL] [Abstract][Full Text] [Related]
53. Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China.
Shi Q; Yin D; Han R; Guo Y; Zheng Y; Wu S; Yang Y; Li S; Zhang R; Hu F
Clin Infect Dis; 2020 Dec; 71(Suppl 4):S436-S439. PubMed ID: 33367577
[TBL] [Abstract][Full Text] [Related]
54. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
[TBL] [Abstract][Full Text] [Related]
55. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
[TBL] [Abstract][Full Text] [Related]
56. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity.
Oueslati S; Iorga BI; Tlili L; Exilie C; Zavala A; Dortet L; Jousset AB; Bernabeu S; Bonnin RA; Naas T
J Antimicrob Chemother; 2019 Aug; 74(8):2239-2246. PubMed ID: 31127297
[TBL] [Abstract][Full Text] [Related]
57. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.
Both A; Büttner H; Huang J; Perbandt M; Belmar Campos C; Christner M; Maurer FP; Kluge S; König C; Aepfelbacher M; Wichmann D; Rohde H
J Antimicrob Chemother; 2017 Sep; 72(9):2483-2488. PubMed ID: 28637339
[TBL] [Abstract][Full Text] [Related]
58. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
59. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
[TBL] [Abstract][Full Text] [Related]
60. Study of
Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
